A HANC Risk Stratification Score for Antiplatelet Therapy Optimization with Low-Dose Prasugrel in Taiwanese Acute Coronary Syndrome Patients from the Switch Study.

ABSTRACT:

Background

A significant proportion of acute coronary syndrome (ACS) patients experience high on-treatment platelet reactivity (HPR) on clopidogrel-based dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI).

Objectives

This study assessed key independent risk factors associated with significant HPR risk on clopidogrel, but not prasugrel, in the Switch Study cohort of 200 Taiwanese ACS patients who switched from clopidogrel to low-dose prasugrel for maintenance DAPT after PCI.

Methods

Univariate analysis and stepwise multivariate logistic regression analysis were conducted to identify key independent risk factors for HPR on clopidogrel, but not prasugrel.

Results

A HANC [H: low hemoglobin (< 13 g/dL for men and < 12 g/dL for women); A:

SUBMITTER: Lee WL 

PROVIDER: S-EPMC9692225 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature